BIOVIE INC.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 15, 2025
BIVI$1.30-2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Year Ended · Year Ended | |||
|---|---|---|---|
| June 30, 2025 · June 30, 2024 | |||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss | $(17,542,120) | $(32,120,533) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Amortization of intangible assets | 229,377 | 229,377 | |
| Stock based compensation - restricted stock units and restricted shares | 1,202,809 | 1,763,450 | |
| Stock based compensation expense - stock options | 1,195,447 | 2,823,764 | |
| Stock based compensation expense - issuance of common stock for services rendered | 73,680 | 72,900 | |
| Amortization of financing costs | 11,820 | 108,751 | |
| Accretion of unearned loan discount | 111,212 | 1,023,145 | |
| Accretion of loan premium | 25,758 | 236,970 | |
| Realized gain on maturity of available-for sale | - | (223,865) | |
| Non-cash lease expense from right-of-use assets | 67,073 | 49,346 | |
| Gain on termination of operating lease | - | (5,215) | |
| Change in fair value of derivative liabilities | (3,771) | (1,816,271) | |
| Changes in operating assets and liabilities: | |||
| Grant receivable | (2,104,050) | - | |
| Prepaid and other current assets | (845,505) | (101,866) | |
| Accounts payable and accrued expenses | (1,386,592) | 110,653 | |
| Operating lease liabilities | (60,343) | (47,245) | |
| Other current liabilities | - | (48,385) | |
| Net cash used in operating activities | (19,025,205) | (27,945,024) | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Proceeds from U.S. Treasury Bills (available-for-sale) | - | 14,525,000 | |
| Net cash provided by investing activities | - | 14,525,000 | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Net proceeds from issuance of common stock | 15,674,613 | 27,802,939 | |
| Proceeds from exercise of warrants | 2,901,341 | (10,000,000) | |
| Payment of loan premium | (850,000) | - | |
| Payments of note payable | (5,000,000) | - | |
| Net cash provided by financing activities | 12,725,954 | 17,802,939 | |
| Net change in cash and cash equivalents | (6,299,251) | 4,382,915 | |
| Cash and cash equivalents, beginning of period | $23,843,798 | $19,460,883 | |
| Cash and cash equivalents, end of period | $17,544,547 | $23,843,798 | |
| SUPPLEMENTAL CASH FLOW INFORMATION: | |||
| Cash paid for interest | $183,930 | $1,525,056 | |
| SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES: | |||
| Right of use assets obtained in exchange for lease obligations | $ | - | $432,192 |
| Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement | $ | - | $176,591 |
| Deemed dividend for ratchet adjustment to warrants | $369,465 | $886,423 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.